U.S. Markets close in 53 mins

Major Stem Cell Breakthroughs Giving Investors Big Opportunity

HENDERSON, NV / ACCESSWIRE / September 14, 2018 / Last week, Sangamo Therapeutics became the first company to edit a patient's DNA inside the body, usually the process is done outside the body. This is one in what could be many breakthroughs in the Stem Cell industry.

One stock leading that push has been BioRestorative Therapies, Inc. (BRTX). The stock has been receiving increased attention by the street. If this is your first time hearing about BRTX make sure you start doing your own due diligence immediately. As BRTX prepares for its Phase 2 clinical trial using BRTX-100 to treat chronic lumbar disc disease, the company is flying under the radar of most investors, which presents a great opportunity to investors that are currently in the know on BRTX. The company just had very important, as well as favorable news which could lead to even more developments for the company. Keep BRTX on your radar because missing out on this very innovative and interesting company would be very disappointing.

This may be the ideal time to take a look at BRTX.

These biotechnology companies are making waves in stem cell news and beyond: BioRestorative Therapies, Inc. (BRTX), Cara Therapeutics, Inc. (CARA), Geron Corporation (GERN), Insys Therapeutics, Inc. (INSY), and Sangamo Therapeutics, Inc. (SGMO).

BioRestorative Therapies, Inc. (BRTX)

Market Cap: $13.68M Share Price: $1.68

BioRestorative Therapies, Inc. (BRTX), a life sciences company focused on stem cell-based therapies, just announced that the Journal of Translational Medicine has published the results of the Company's study evaluating the benefits of long-term hypoxic (low oxygen) culturing of human bone marrow-derived mesenchymal stem cells (cells used in the Company's product, BRTX-100). The study included data on cell fitness and whole genome expression and discussed its implication on cellular therapies targeting intervertebral discs and its microenvironment.

The FDA has authorized BioRestorative to commence a Phase 2 clinical trial using hypoxic cultured bone marrow-derived mesenchymal stem cells in its lead candidate, BRTX-100, to treat chronic lower back pain.

Cara Therapeutics, Inc. (CARA)

Market Cap: $786.98M Share Price: $20.03

Cara Therapeutics, Inc. (CARA), a U.S. biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, announced announced a presentation at the 27th European Academy of Dermatology & Venereology Congress (EADV), to be held September 12-16, 2018 in Paris.

Geron Corporation, Inc. (GERN)

Market Cap: $1.1B Share Price: $5.99

Geron Corporation (GERN) is a clinical-stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. On the company's recent earnings conference call, CEO Scarlett began by handing off to CFO Bloom. She reported on Geron's net loss for the quarter of $6.9 million in contrast to the comparable quarter in 2017 loss of $6.4 million. Geron's Q2, 2018 net reflects $3.2 million of research and development expenses for its share of costs under the collaboration agreement together with $4.2 million of general and administrative expenses.

Insys Therapeutics, Inc. (INSY)

Market Cap: $627.39M Share Price: $8.47

Insys Therapeutics, Inc announced the U.S. Food and Drug Administration declined to approve its opioid painkiller, citing potential safety concerns. Insys' treatment is an under-the-tongue spray formulation of the opioid buprenorphine that was under review to treat moderate-to-severe pain. Despite the news the stock maintained investor interest. Then last Thursday Maryland authorities announced charges Thursday against an Arizona-based drugmaker that they say engaged in a nationwide scheme "characterized by extraordinary misconduct" to boost profits amid the coast-to-coast opioid epidemic.

Sangamo Therapeutics, Inc. (SGMO)

Market Cap: $1.47B Share Price: $14.62

Sangamo Therapeutics Inc. stock dropped on heavy trading last Wednesday trade after the company released early results from a gene-editing trial for a rare metabolic disorder called Hunter syndrome.

The trial marked the first instance of gene editing, or adding a new copy of a gene into the DNA of a patient's cells, completed inside the body, or in vivo, Sangamo said. In other types of gene editing and gene therapies that have been tested or approved in the U.S., the process is completed outside of the body.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and sixteen thousand dollars total by Regal Consulting. LLC, for news commentary articles for BRTX. BRTX and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. ACR Communications, LLC. and the hiring party Regal Consulting, LLC. may buy or sell additional shares of BRTX in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

For Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager

Email: info@microcapspecualtors.com

Phone: 1-702-720-6310

Country: United States

Website: http://microcapspeculators.com/

SOURCE: ACR Communications, LLC

https://www.accesswire.com/511990/Major-Stem-Cell-Breakthroughs-Giving-Investors-Big-Opportunity